BTNX’s Rapid Response COVID-19 Antigen Test Device is designed to detect the SARS-CoV-2 viral nucleocapsid proteins. Mutations of the nucleocapsid proteins for the Omicron variant include P13L, Δ31-33, R203K, and G204R. BTNX has urgently analyzed the sequences from the Omicron variant to understand the implication of these mutations.

Based on the preliminary analysis, we anticipate that the Omicron variant will be detectable by the Rapid Response COVID-19 Antigen Test Device. BTNX will conduct in-vitro studies to confirm the effect on test performance. The results will be made available as soon as the investigations are concluded. BTNX continues to follow the latest findings on COVID-19 and remain committed to maintaining the highest level of excellency in our products.

View full statement here.